Omnix Medical Launches New Horizon Europe PEPTAMR Infectious Disease Consortium
EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobialOMN6Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired…
Read the full articleYou might also wanna read
ABPI response to DHSC antimicrobial resistance research funding
UK government announces £39 million funding for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF).
New project targets recurrent urinary tract infections using phages
Researchers at the HUN-REN Biological Research Centre, Szeged are participating in a €15 million Horizon Europe program that will investigat
Al rescate de un antibiótico ‘olvidado’: un medicamento de los años 80 demuestra su eficacia contra las superbacterias
Cerca de 24.000 personas mueren cada año en España por la resistencia a los antibióticos
Independent study: CARB-X-supported antibiotic projects are five times more likely to reach clinical trials
CARB-X today welcomed the publication of the first-ever independent, peer reviewed evaluation of a push incentive to address antimicrobial r
carb-x.org·8d agoCelebrating UK progress in tackling the global threat of antimicrobial resistance (AMR)
World Antimicrobial Awareness Week blog by Amit Aggarwal, ABPI Executive Director, Medical Affairs and Strategic Partnerships.
Celltrion's High-Margin Follow-On Products Expand Share in Europe
Celltrion's high-margin follow-on biosimilars are expanding their share across Europe, with Omlyclo reaching 16% and Vegzelma and Yuflyma ho
Comments
Sign in to join the conversation.
No comments yet. Be the first.